RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST) PROGRESSING DESPITE PRIOR TREATMENT WITH AT LEAST IMATINIB (IM) AND SUNITINIB (SU) : GRID TRIAL

Author(s):
Nishida, T.; Casali, P.G.; Reichardt, P.; Kang, Y.K.; Blay, J.Y.; Joensuu, H.; Maki, R.G.; Rutkowski, P.; Hohenberger, P.; Gelderblom, H.; Leahy, M.G.; Mehren, M. von; Schoffski, P.; Blackstein, M.E.; Cesne, A.L.; Badalamenti, G.; Xu, J.M.; Laurent, D.; Kuss, I.; Demetri, G.D.; GRID Investigators
Published
2012
Publication type
Article / Letter to editor
Date issued
2012-10-31
Language
English
Is part of
Annals of Oncology (2012), Vol. 23, p. 20-20
hdl
1887/97719